SFSusan Ferry

Susan Ferry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan Ferry has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Carol Van Ryzin

    Metabolic Medicine Branch, National Human Genome Research Institute National Institutes of Health (NIH) Bethesda Maryland USA

    2 shared publications
  • Charles P. Venditti

    National Human Genome Research Institute, National Institutes of Health Bethesda Maryland USA

    2 shared publications
  • Irini Manoli

    Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland

    2 shared publications
  • Jennifer L. Sloan

    National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    2 shared publications
  • Abigael Gebremariam

    Metabolic Medicine Branch, National Human Genome Research Institute National Institutes of Health (NIH) Bethesda Maryland USA

    1 shared publication
  • Alexandra R. Pass

    Metabolic Medicine Branch, National Human Genome Research Institute National Institutes of Health (NIH) Bethesda Maryland USA

    1 shared publication

Latest Publications

  • Open Access

    Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia

    by Irini Manoli, Abigael Gebremariam, Samantha McCoy, Alexandra R. Pass, Jack Gagné, Camryn Hall, Susan Ferry, Carol Van Ryzin, Jennifer L. Sloan, Elisa Sacchetti, et al.

    Methylmalonic Acidemia (MMA) is a heterogenous group of inborn errors of metabolism caused by a defect in the methylmalonyl‐CoA mutase (MMUT) enzyme or the synthesis and transport of its cofactor, 5′‐deoxy‐adenosylcobalamin. It is characterized by life‐threatening episodes of ketoacidosis, chronic kidney disease, and other multiorgan complications. Liver transplantation can improve patient stability and survival and thus provides clinical and biochemical benchmarks for the development of hepatocyte‐targeted genomic therapies. Data are presented from a US natural history protocol that evaluated subjects with different types of MMA including mut‐type (N = 91), cblB‐type (15), and cblA‐type MMA (17), as well as from an Italian cohort of mut‐type (N = 19) and cblB‐type MMA (N = 2) subjects, including data before and after organ transplantation in both cohorts. Canonical metabolic markers, such as serum methylmalonic acid and propionylcarnitine, are variable and affected by dietary intake and renal function. We have therefore explored the use of the 1‐13C‐propionate oxidation breath test (POBT) to measure metabolic capacity and the changes in circulating proteins to assess mitochondrial dysfunction (fibroblast growth factor 21 [FGF21] and growth differentiation factor 15 [GDF15]) and kidney injury (lipocalin‐2 [LCN2]). Biomarker concentrations are higher in patients with the severe mut0‐type and cblB‐type MMA, correlate with a decreased POBT, and show a significant response postliver transplant. Additional circulating and imaging markers to assess disease burden are necessary to monitor disease progression. A combination of biomarkers reflecting disease severity and multisystem involvement will be needed to help stratify patients for clinical trials and assess the efficacy of new therapies for MMA.


  • Newborn screening and optimized hydroxocobalamin and dietary therapy lead to improved neurocognitive outcomes in early onset cobalamin C deficiency

    by Irini Manoli, Sho Yano, Jennifer Sloan, Wadih Zein, Laryssa Huryn, Joseph Snow, Audrey Thurm, Carol Van Ryzin, Susan Ferry, Jennifer Myles, et al.